Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology
Joanna C. Neill, B. Terence Grayson, Béla Kiss, et al.
European Neuropsychopharmacology (2015) Vol. 26, Iss. 1, pp. 3-14
Open Access | Times Cited: 82

Showing 26-50 of 82 citing articles:

New drugs in psychiatry: focus on new pharmacological targets
Filippo Caraci, Gian Marco Leggio, Salvatore Salomone, et al.
F1000Research (2017) Vol. 6, pp. 397-397
Open Access | Times Cited: 32
The Role of Dopamine D3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens
Mei Huang, Wenqi He, Béla Kiss, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 371, Iss. 2, pp. 517-525
Open Access | Times Cited: 26
Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques
Ginetta Collo, Armida Mucci, Giulia Maria Giordano, et al.
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 24
The role of dopamine receptors in lymphocytes and their changes in schizophrenia
Maria Aránzazu Penedo, T. Rivera-Baltanás, Daniel Pérez-Rodríguez, et al.
Brain Behavior & Immunity - Health (2021) Vol. 12, pp. 100199-100199
Open Access | Times Cited: 21
Cognitive Effects of Lurasidone and Cariprazine: A Mini Systematic Review
Miriam Olivola, Nicola Bassetti, Serena Parente, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 12, pp. 2431-2446
Closed Access | Times Cited: 8
RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia
Lakshmi Rajagopal, Sunoh Kwon, Mei Huang, et al.
Behavioural Brain Research (2017) Vol. 332, pp. 180-199
Closed Access | Times Cited: 26
Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder
Viktor Román, Nika Adham, Andrew Foley, et al.
Psychopharmacology (2021) Vol. 238, Iss. 9, pp. 2381-2392
Open Access | Times Cited: 20
Case Series: Cariprazine for treatment of methamphetamine use disorder
Thanh Thuy Truong, Benjamin Li
American Journal on Addictions (2021) Vol. 31, Iss. 1, pp. 85-88
Closed Access | Times Cited: 19
The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices
Maria Meier, Clément E. Lemercier, Christoph Kulisch, et al.
British Journal of Pharmacology (2019) Vol. 177, Iss. 7, pp. 1622-1634
Open Access | Times Cited: 22
The preclinical discovery and development of cariprazine for the treatment of schizophrenia
Anna Wesołowska, Anna Partyka, Magdalena Jastrzębska‐Więsek, et al.
Expert Opinion on Drug Discovery (2018) Vol. 13, Iss. 8, pp. 779-790
Closed Access | Times Cited: 21
Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction
Lakshmi Rajagopal, D.K. SONI, Herbert Y. Meltzer
Behavioural Brain Research (2018) Vol. 350, pp. 31-43
Closed Access | Times Cited: 21
Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands
Edward Ofori, Xue Y. Zhu, Jagan R. Etukala, et al.
Bioorganic & Medicinal Chemistry (2016) Vol. 24, Iss. 16, pp. 3464-3471
Open Access | Times Cited: 20
Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications
Lakshmi N. Yatham, Eduard Vieta, Roger S. McIntyre, et al.
The Primary Care Companion For CNS Disorders (2020) Vol. 22, Iss. 5
Open Access | Times Cited: 18
Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine
Yong Kee Choi, Nika Adham, Béla Kiss, et al.
CNS Spectrums (2017) Vol. 22, Iss. 6, pp. 484-494
Open Access | Times Cited: 21
The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task
Samuel A. Barnes, Jared W. Young, Athina Markou, et al.
Psychopharmacology (2018) Vol. 235, Iss. 5, pp. 1403-1414
Open Access | Times Cited: 19
Cariprazine for the treatment of bipolar depression: a review
Renee‐Marie Ragguett, Roger S. McIntyre
Expert Review of Neurotherapeutics (2019) Vol. 19, Iss. 4, pp. 317-323
Closed Access | Times Cited: 18
Sustained NMDA receptor hypofunction impairs brain-derived neurotropic factor signalling in the PFC, but not in the hippocampus, and disturbs PFC-dependent cognition in mice
Sara R. Tanqueiro, Francisco M. Mouro, Catarina B. Ferreira, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 6, pp. 730-743
Open Access | Times Cited: 13
Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation
Samantha L. McLean, Michael Harte, Joanna C. Neill, et al.
Journal of Psychopharmacology (2017) Vol. 31, Iss. 6, pp. 660-666
Open Access | Times Cited: 14
A greater tendency for representation mediated learning in a ketamine mouse model of schizophrenia.
Ming Teng Koh, Paige S Ahrens, Michela Gallagher
Behavioral Neuroscience (2018) Vol. 132, Iss. 2, pp. 106-113
Open Access | Times Cited: 12
Alpha 7 nicotinic receptor agonist and positive allosteric modulators improved social and molecular deficits of MK-801 model of schizophrenia in rats
Gökhan Ünal, Hatice Bekçi, Ahmet Cumaoğlu, et al.
Pharmacology Biochemistry and Behavior (2020) Vol. 193, pp. 172916-172916
Closed Access | Times Cited: 11
Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
Borjanka Batinić, Ivan Ristić, Milica Žugić, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 10
The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia
Jessica Brown, Luisa Iacovelli, Gabriele Di Cicco, et al.
Neuropharmacology (2022) Vol. 208, pp. 108982-108982
Open Access | Times Cited: 7
Agmatine-attenuated cognitive and social deficits in subchronic MK-801 model of schizophrenia in rats
Gökhan Ünal, Alpay Ateş, Feyza Arıcıoğlu
Psychiatry and Clinical Psychopharmacology (2018) Vol. 28, Iss. 3, pp. 245-253
Open Access | Times Cited: 11
The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
Sarah Delcourte, Charles R. Ashby, Renaud Rovera, et al.
CNS Neuroscience & Therapeutics (2018) Vol. 24, Iss. 12, pp. 1129-1139
Open Access | Times Cited: 11
The prospects of cariprazine in the treatment of schizophrenia
Jonathan R. Scarff
Therapeutic Advances in Psychopharmacology (2017) Vol. 7, Iss. 11, pp. 237-239
Open Access | Times Cited: 10

Scroll to top